Celcuity CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits IRC174Expenditures
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits IRC174Expenditures at other companies
Other financials
Where this comes from
Reported directly by Celcuity in its filing.
Tagged under the XBRL concept CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures.
The official record: Celcuity’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celcuity's deferred tax assets tax deferred expense compensation and benefits irc174expenditures.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celcuity's deferred tax assets tax deferred expense compensation and benefits irc174expenditures?
- Celcuity (CELC) reported deferred tax assets tax deferred expense compensation and benefits irc174expenditures of $48.07M in Q4 2025.
- What is the long-term trend for Celcuity's deferred tax assets tax deferred expense compensation and benefits irc174expenditures?
- Over 3 years (2022 to 2025), Celcuity's deferred tax assets tax deferred expense compensation and benefits irc174expenditures has grown at a 143.6% compound annual growth rate (CAGR), from $3.33M to $48.07M.
- What does deferred tax assets tax deferred expense compensation and benefits irc174expenditures mean?
- This represents the deferred tax asset generated by the capitalization and amortization of research and development expenditures, specifically related to compensation and benefits under IRC Section 174. It captures the tax benefit of future deductions that are deferred due to current tax law requirements for R&D cost treatment. This metric is critical for biotechnology firms managing the tax implications of heavy R&D investment cycles.